The news is directly about Generation Bio. The Outperform rating suggests that the analyst expects the stock to do better than the market average, which is positive. However, the lowering of the price target from $11 to $9 indicates a reduced future valuation, which could have a negative impact. The net effect is likely to be neutral in the short term.